DHT and Hair Loss: The Follicle Miniaturisation Biology Every Man Should Know
Most men know they are losing hair. Very few understand exactly why — and that understanding makes a critical difference in whether the treatment they choose actually works.
Androgenetic alopecia — male and female pattern hair loss — affects approximately 50% of men by age 50. Despite its prevalence, most people do not understand the hormone driving it, the specific mechanism of damage, or critically — why some treatments work and others do not. Understanding DHT and follicle miniaturisation is the foundation for every meaningful hair loss intervention.
The most important insight is this: hair loss caused by DHT is progressive but not inevitable at every follicle. Follicles exist on a spectrum of miniaturisation from fully healthy to completely scarred. Treatment is most effective — and sometimes fully reversible — when initiated before follicles reach the irreversible end of that spectrum. This is why early action matters so much more than it does for almost any other aesthetic concern.
What DHT Is and Where It Comes From
DHT (dihydrotestosterone) is an androgenic hormone derived from testosterone through a reaction catalysed by the enzyme 5-alpha reductase (5AR). This enzyme is present in multiple tissues including the liver, skin, and prostate, but two isoforms are particularly relevant to hair loss:
- Type 1 5AR: Predominant in the liver, sebaceous glands, and skin — produces some DHT, particularly relevant to acne and sebum production
- Type 2 5AR: Predominant in hair follicles, prostate, and genital skin — the primary isoform responsible for scalp DHT production and therefore the primary target of DHT-blocking medications
DHT binds to androgen receptors with approximately 2–3 times the affinity of testosterone itself — it is the more potent androgen. In most tissues of the body, this potency is either neutral or beneficial. In scalp hair follicles of genetically susceptible individuals, this potency becomes destructive through a specific and well-characterised mechanism.
The Mechanism of Follicle Miniaturisation
Normal scalp hair follicles cycle through three phases: anagen (growth, lasting 2–7 years), catagen (brief transition, 2–3 weeks), and telogen (resting, 3–4 months). The length of the anagen phase determines how long the hair grows before shedding. Healthy follicles remain in anagen for years at a time, producing long, thick terminal hair.
In individuals genetically susceptible to androgenetic alopecia, scalp follicles express higher levels of androgen receptors and often higher Type 2 5AR activity locally. When DHT binds to these receptors, it initiates a process called follicular miniaturisation:
- The anagen phase shortens progressively with each hair cycle — from years to months to weeks
- The follicle itself physically shrinks, with a smaller dermal papilla and reduced vascular supply
- Each successive hair produced is shorter, thinner, and lighter (lower melanin content)
- The hair transitions from thick terminal hair to thin, short, colourless vellus hair — the barely visible “peach fuzz” of advanced baldness
- In fully progressed follicles, the structure becomes permanently fibrotic and inactive
This process follows characteristic patterns: the Norwood-Hamilton scale in men (recession at temples and crown) and the Ludwig scale in women (diffuse thinning at the crown). The pattern reflects differential expression of androgen receptors — follicles in DHT-sensitive zones have higher receptor density than those at the occiput (back of head), which is why hair transplanted from the back of the head retains its resistance to DHT even in the new location.
Follicle miniaturisation is a spectrum — from fully healthy to completely fibrotic. Follicles in early and mid-miniaturisation retain their progenitor cells and dermal papilla architecture, allowing rescue with appropriate treatment. Fully fibrotic follicles where the dermal papilla has been replaced by fibrous tissue cannot be recovered — only hair transplantation addresses them. Most patients delay treatment until loss is obvious, which is precisely when a significant portion of follicles have already crossed the irreversible threshold.
Why Testosterone Level Does Not Determine Hair Loss Speed
This is probably the most widely misunderstood aspect of androgenetic alopecia. Men with high testosterone do not necessarily lose hair faster. Bald men do not have higher testosterone than non-bald men on average. What determines hair loss rate is not the absolute testosterone level but:
- Genetic sensitivity of follicles to DHT: Determined by androgen receptor expression and sensitivity in scalp follicle cells — primarily a genetic inheritance from either parent
- Local 5AR activity in the scalp: How efficiently testosterone is converted to DHT at the follicle level — varies between individuals independently of total testosterone
- Number of androgen receptor copies: Influenced by a polymorphism in the androgen receptor gene on the X chromosome (inherited from the mother)
A man with low-normal testosterone but highly sensitive follicles can experience aggressive hair loss. A man with high testosterone and follicles with low DHT sensitivity may keep his hair into his 70s. This is why testosterone supplementation does not inherently accelerate hair loss — it depends entirely on the individual’s follicle sensitivity profile.
The most effective approach for androgenetic alopecia combines a DHT blocker to slow the damage with a growth stimulant to strengthen what remains. Doing one without the other is like bailing water while the tap is still running — or blocking the tap while ignoring the water already on the floor.
Dr. Dinesh Kumar, MBBS, LCP-Certified — Vivardi Clinics RawangEvidence-Based Treatment Options
| Treatment | How It Works | Targets DHT? | Best For |
|---|---|---|---|
| Finasteride (oral) | Type 2 5AR inhibitor — blocks DHT conversion at the follicle | Yes — reduces scalp DHT ~70% | Men with AGA, progressive loss |
| Minoxidil (oral) | Vasodilator — extends anagen phase via prostaglandin E2 | No — works independently | Men and women, all stages |
| QR678 Neo | Growth factor cocktail injected at follicle depth | No — directly stimulates follicle | Active miniaturisation, recovery |
| PRP Hair | PDGF, VEGF, IGF-1 stimulate follicle biology | No — complementary mechanism | Complement to DHT inhibition |
What About Women and DHT-Related Hair Loss?
Female pattern hair loss (FPHL) also involves androgens, but the relationship is more complex than in men. Women have much lower total androgen levels, but their scalp follicles can still miniaturise in response to DHT — particularly in women with PCOS (where androgen levels are elevated), post-menopausal women (where the oestrogen-to-androgen ratio shifts toward androgen dominance), or women with elevated 5AR activity.
Treatment in women differs significantly from men. DHT-blocking medications (finasteride, dutasteride) are contraindicated in premenopausal women due to teratogenic risk. Treatment typically involves oral or topical minoxidil, spironolactone (anti-androgen), QR678 Neo, and PRP. A proper hormonal assessment is essential for women with hair loss.
Frequently Asked Questions
Scalp Health and DHT: The Inflammatory Component
Androgenetic alopecia is increasingly understood as not purely a DHT-mediated process but also an inflammatory one. Histological studies of balding scalp tissue consistently show lymphocytic infiltrates — immune cells — around miniaturising follicles, particularly at the level of the bulge (where follicle stem cells reside). This inflammation, which in some aspects resembles a low-grade autoimmune process, appears to accelerate miniaturisation beyond what DHT alone would produce.
This is supported clinically by the observation that scalp microbiome disruption, seborrhoeic dermatitis (dandruff), and chronic scalp inflammation are all associated with accelerated hair loss. Malassezia fungi that drive dandruff trigger inflammatory cytokines around follicles that compound DHT-mediated damage. Managing scalp health through appropriate antifungal treatment when indicated, reducing pro-inflammatory sebum, and clinical treatments with anti-inflammatory effects (particularly PDRN in Plinest) adds another dimension to hair loss management beyond DHT blockade alone.
Nutritional Support for Hair Follicle Health
While nutrition cannot reverse genetic hair loss, nutritional deficiencies are frequently overlooked amplifiers. Several micronutrient deficiencies are particularly relevant and correctable:
- Iron deficiency: Even without frank anaemia, ferritin levels below 40 ng/mL are associated with excessive hair shedding. A ferritin test — not just standard haemoglobin — is needed to identify this.
- Zinc: Kofaktor for 5-alpha reductase, collagen synthesis, and follicle cell proliferation. Deficiency exacerbates androgenetic and telogen effluvium hair loss.
- Vitamin D: VDR (vitamin D receptor) in hair follicles is required for normal anagen initiation. Deficiency is extremely common in Malaysia despite tropical sun exposure, due to sun avoidance and indoor lifestyles.
- Biotin: Deficiency causes hair loss, but deficiency is rare in people eating a normal diet. Biotin supplementation in non-deficient individuals does not produce clinically meaningful hair growth despite heavy marketing.
A simple blood panel covering ferritin, zinc, 25-OH vitamin D, and thyroid function (often overlooked in hair loss) identifies correctable deficiencies that, when addressed, often significantly improve the response to other hair loss treatments.
